Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method

Zheng, Xin; Gao, Huitao; Cui, Xiaoxu; Zhang, Yanbao; Chen, Rui; Wang, Yaqin; Lauruol, Pauline; Wang, Hongyun

doi:10.1016/j.jchromb.2021.122585

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The test treatment in this statistical analysis was S06593, and S05590 and amlodipine served as references. Table 3 provides the summarized results of geometric mean ratios (GMRs) and the corresponding 90% confidence intervals obtained for the main PK parameters [37].…”

Section: Discussionmentioning

confidence: 99%

“…Plasma concentrations of perindopril, perindoprilat and indapamide were determined through a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method at PUMCH [37]. Another LC-MS/MS method was independently developed and validated for amlodipine at the Centre for Drug Metabolism and Pharmacokinetics Research (DMPK Centre), Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.…”

Section: Bioanalytical Methodsmentioning

confidence: 99%

“…Descriptive statistics for PK parameters is shown in Table 2 [37]. All results were obtained on the basis of the data of the 42 participants included for each analyte.…”

Section: Pharmacokinetic Evaluationmentioning

confidence: 99%

See 2 more Smart Citations

Potential pharmacokinetic interactions in fixed-dose combinations of perindopril/indapamide/amlodipine compared with perindopril/indapamide and amlodipine in healthy Chinese volunteers

Gao

Zheng

et al. 2023

Acta Materia Medica

Self Cite

View full text Add to dashboard Cite

S05590 is a fixed-dose combination of perindopril tert-butylamine 4 mg/indapamide 1.25 mg, and S06593 is a fixed-dose combination of perindopril arginine 5 mg/indapamide 1.25 mg/amlodipine 5 mg. The purpose of this study was to determine whether pharmacokinetic interactions exist among the components of S06593, compared with S05590 and amlodipine as reference drugs, in healthy Chinese male volunteers after a single oral administration under fasting conditions. A single-center, open-label, randomized, three-period, six-way crossover study was conducted. A total of 42 participants were enrolled and randomized to receive S05590 plus amlodipine, or S06593. The doses of perindopril were 3.34 mg in both S05590 and S06593, calculated as free acid. Blood samples were collected in each treatment period to determine the plasma concentrations of perindopril, indapamide and amlodipine, as well as perindoprilat, the main metabolite of perindopril. A total of 39 participants completed this study. The 90% confidence intervals of the geometric mean ratios of Cmax, AUC0-t and AUC0-∞ for perindopril, perindoprilat, indapamide and amlodipine were all within 80.00–125.00%, thus indicating that S05590 plus amlodipine and S06593 were pharmacokinetically equivalent. During the study, only one serious emergent adverse event was reported, which was deemed not to be associated with the study drug. No serious treatment-associated adverse events were observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Bioanalytical Methodsmentioning

confidence: 99%